Investindustrial Completes Acquisition of Proveris

Investindustrial has acquired Proveris Scientific Corporation for an undisclosed amount.

Proveris Scientific is a specialized company that assists pharmaceutical companies in developing orally inhaled and nasal drug products (OINDPs), aiming to accelerate their market entry and reduce development costs.

This acquisition marks a strategic expansion for Investindustrial into the pharmaceutical services sector, leveraging Proveris's established expertise in a critical area of drug development.

For over two decades, Proveris Scientific has focused on understanding and controlling the complex relationships among drug delivery devices, formulations, and human usage that drive OINDP performance.

The company applies intelligent automation technology, modern data analysis, and proven experimentation techniques to achieve superior product knowledge.

Proveris works closely with pharmaceutical companies, device suppliers, contract organizations, and regulatory agencies, offering extensive product testing and unique insights.

Its patented Proveris by Design™ process identifies human usage performance according to FDA and ICH guidelines, assisting with device selection, developing testing strategies, and providing instruments for research and quality assurance.

Proveris is certified to ISO 9001:2015.

The acquisition by Investindustrial is expected to provide Proveris Scientific with additional resources and strategic support to further enhance its offerings and expand its global reach.

Investindustrial's investment aims to capitalize on Proveris's specialized knowledge and market position in OINDP development, a sector critical for delivering effective therapies to patients.

Synergies are anticipated through accelerated innovation and the potential to broaden the application of Proveris's advanced testing methodologies.

The combined entity is poised to continue elevating industry standards for OINDP development.

By integrating Investindustrial's strategic capabilities with Proveris's scientific and technological expertise, the acquisition is set to strengthen Proveris's ability to deliver value-oriented solutions, ultimately helping more effective therapies reach patients faster.